Bausch Health Companies Inc.

Drug pipeline (107)

Asset	Stage	Revenue	Trials	Status
Acetaminophen	approved	—	78	approved
Acyclovir	approved	—	0	—
Adapalene	approved	—	4	approved
Albuterol Sulfate	approved	—	3	approved
AMINOPHYLLINE	approved	—	0	—

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (194)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02047604	phase2	completed	2013-12-01	2017-02-23	Bausch Health Americas, Inc.	(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
NCT00679432	phase3	completed	2008-06-01	2010-05-01	Bausch Health Americas, Inc.	(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
NCT00679380	phase3	completed	2008-06-01	2010-02-01	Bausch Health Americas, Inc.	(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
NCT00801723	phase3	completed	2008-12-01	2011-05-01	Bausch Health Americas, Inc.	(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
NCT01100112	phase3	completed	2010-02-01	2010-07-01	Bausch Health Americas, Inc.	(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

FDA applications (172)

Application

Type

Applicant

Products

ANDA 040700

ANDA

BAUSCH HEALTH AMERICAS INC

ANDA 060471

ANDA

VALEANT PHARMACEUTICALS INTERNATIONAL

ANDA 062279

ANDA

VALEANT PHARMACEUTICALS LUXEMBOURG SARL

ANDA 062483

ANDA

VALEANT PHARMACEUTICALS LUXEMBOURG SARL

ANDA 064039

ANDA

BAUSCH HEALTH US LLC